DOI:
10.1055/s-00000034
Klinische Pädiatrie
LinksClose Window
References
Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, Appelbaum FR.
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia. Southwest Oncology Group Study.
Leuk Res 1999; 23: 787-794
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.